Navigation Links
HemoShear to Develop Human Cancer Models to Improve Industry Success Rates in New Anticancer Drug Development

CHARLOTTESVILLE, Va., Nov. 7, 2013 /PRNewswire/ -- Safer and more effective anticancer drugs may soon be developed thanks to a Small Business Innovation Research contract recently awarded to HemoShear by the National Cancer Institute (NCI) of the U.S. National Institutes of Health (NIH).  HemoShear, LLC, is the pharmaceutical industry's leading developer of the most advanced human biology systems for applications in drug research and development. 


Anticancer drugs continue to suffer the highest rate of failure in clinical trials as compared with other therapeutic areas.  According to the NCI, "There is a critical need to improve the accuracy of preclinical drug efficacy screening and testing through the development of [laboratory-based] culture systems that more effectively mimic the [human] environment.  Systems to properly recreate the tumor microenvironment are lacking and [are] essential to advance the discovery and development of effective anticancer agents."

HemoShear's contract with the National Cancer Institute will support the development of human cell-based systems that accurately replicate the biology of lung and pancreatic tumors, two of the deadliest groups of tumors.  "Lung and pancreatic cancer are terrible diseases that have no effective treatments," said Dr. Brian Wamhoff, HemoShear co-founder and Vice President of R&D.  "We are using our innovative science to enable the discovery of new treatments for cancer patients.  While billions of dollars continue to be spent on researching and developing new cancer therapies, their success rates in clinical trials are not improving.  Imagine a human tumor on the laboratory bench that responds to new therapies as if it were in the human body.  That is what our science is capable of achieving," said Dr. Wamhoff.

HemoShear's success in this initial stage of tumor system development will lead to development of other cancer tumor systems, to systems that replicate metastasis and potentially to new treatments for patient-specific tumors. 

"This is HemoShear's third major area of SBIR funding from separate divisions of the NIH in three years.  We are grateful for the strong support of NIH and the scientific community.  We believe that HemoShear science will yield safer and more effective therapies while avoiding costly new drug failures," said Jim Powers, HemoShear's CEO.

About HemoShear

HemoShear has developed the only technology of its kind that accurately replicates human organ system and disease biology in the laboratory.  HemoShear science is rapidly being adopted by leading pharmaceutical and biotechnology companies to make better decisions and select drug candidates with superior efficacy and safety profiles.  Working in partnerships with pharmaceutical, biotechnology and medical device companies, HemoShear generates meaningful data to increase confidence in decision-making and reduce risk of costly failures.

Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. HemoShear Hires Industry Business Development Veteran Vincent Aurentz as Chief Business Officer
2. HemoShear Partners with Expression Analysis (EA) to Develop a Human Drug-Induced Vascular Response Database
3. HemoShear to Present at Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Conference
4. Cato Research Presents at Korea-Maryland, USA BIO EXPO, Drug Development Process and Regulatory Approaches
5. Novogen Launches Joint Venture Aimed At Developing Drugs to Fight Ovarian Cancer
6. Tunisia Hosts First African Summer School on Optics and Applications to Sustainable Development
7. Rancho BioSciences Will Present the Accelerated Cure Project Multiple Sclerosis Data Curation White Paper at the tranSMART Fall Developers Meeting, Paris, November 5-7
8. Clinical Research Site-Expert Johan Karlberg to Lead ACRES Global Network Development
9. Global Sports Development's Symposium on Doping Deepens the Anti-Doping Discussion
10. Cytos Biotechnology Ltd Reports Third Quarter 2013 Financial Results and Recent Developments
11. Biomarker Challenges in Biosimilar Drug Development, New Life Science Webinar Hosted by Xtalks
Post Your Comments:
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... announced the launch of the Supplyframe Design Lab . Located in Pasadena, ... explore the future of how hardware projects are designed, built and brought to ...
(Date:6/23/2016)...  Blueprint Bio, a company dedicated to identifying, protecting ... has closed its Series A funding round, according to ... "We have received a commitment from Forentis Fund that ... meet our current goals," stated Matthew Nunez . ... complete validation on the current projects in our pipeline, ...
Breaking Biology Technology:
(Date:5/12/2016)... 2016 , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: ... for financial services, but it also plays a fundamental part ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
Breaking Biology News(10 mins):